Gliomas present a complex challenge in neuro-oncology, often accompanied by the
debilitating complication of epilepsy. Understanding the biological interaction and common …

Central nervous system (CNS) neoplasms are difficult to treat due to their sensitive location.
Over the past two decades, the availability of patient tumor materials facilitated large scale …

Purpose: Although fewer than 5% of high-grade gliomas (HGG) are BRAF-V600E mutated,
these tumors are notable as BRAF-targeted therapy shows efficacy for some populations …

Aims Mitogen-activated protein kinase (MAPK) pathway alteration is a major oncogenic
driver in paediatric low-grade gliomas (LGG) and some adult gliomas, encompassing BRAF …

The functions of mitochondria, including energy production and biomolecule synthesis, have
been known for a long time. Given the rising incidence of cancer, the role of mitochondria in …

Low-grade gliomas present a formidable challenge in neuro-oncology because of the
challenges imposed by the blood-brain barrier, predilection for the young adult population …

Advanced molecular testing has increasingly become an integral component for accurate
diagnosis of central nervous system (CNS) tumors. We sought to establish the current state …

Glioblastoma (GBM) classification involves a combination of histological and molecular
signatures including IDH1/2 mutation, TERT promoter mutation, and EGFR amplification …

Background Isocitrate dehydrogenase (IDH)-mutant gliomas generally have a better
prognosis than IDH-wild-type glioblastomas, and the extent of resection significantly impacts …

Gliomas are tumors arising in the central nervous system, frequently associated with Class I
mutations and BRAF fusions. These mutations are adverse prognostic factors in juvenile …